OptimizeRx Co. (NASDAQ:OPRX) Given Average Rating of “Moderate Buy” by Brokerages

OptimizeRx Co. (NASDAQ:OPRX) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $10.42.

A number of equities analysts have recently commented on the stock. JMP Securities reduced their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 14th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Stifel Nicolaus dropped their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Roth Mkm restated a “buy” rating and issued a $16.00 price objective (down from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Finally, Royal Bank of Canada dropped their target price on shares of OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th.

Hedge Funds Weigh In On OptimizeRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in OPRX. Summit Securities Group LLC bought a new stake in shares of OptimizeRx in the 2nd quarter valued at about $25,000. BNP Paribas Financial Markets lifted its position in OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after acquiring an additional 2,414 shares during the last quarter. Quest Partners LLC boosted its stake in OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after acquiring an additional 9,739 shares in the last quarter. Connors Investor Services Inc. grew its holdings in OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Barclays PLC increased its position in shares of OptimizeRx by 358.5% during the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after purchasing an additional 21,060 shares in the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Trading Up 1.2 %

NASDAQ OPRX opened at $4.99 on Monday. The stock has a market cap of $91.92 million, a PE ratio of -3.75 and a beta of 1.34. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $16.65. The company’s 50-day moving average price is $5.55 and its 200-day moving average price is $8.01. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.